Glenmark Pharmaceuticals Ltd.
NSE: GLENMARKGlenmark Pharmaceuticals Ltd.: A 30-second snapshot
Glenmark Pharmaceuticals trades at Rs 2,190.30, up 2.39% over the past year but down 9.41% over the last three months and 11.47% below its 52-week high. Trailing PE stands at 46.36 versus a forward PE of 22.73, with ROE of 14.07% and a persistence consistency score of 54/100; mean analyst rating is 1.67 across 11 analysts (1-5 scale, lower = more constructive). News flow across the last 8 tracked articles is entirely positive or neutral, centered on a reported Q1 profit jump and new product launches.
P/E
46.4
Forward P/E
22.7
ROE
+14.1%
Debt / Equity
5.65
Profit Margin
+8.0%
Div. Yield
+0.2%
5Y ROE > 15%
0/5
5Y FCF > 0
2/5
Quality
61/100
News
8 headlines · 6 positive · 0 negative
Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth - CNBC TV18
CNBC TV18
Glenmark Pharma Q1 Results: Profit Rises Exponentially To Rs 483 Crore; Revenue Jumps 23% - NDTV Profit
NDTV Profit
Glenmark Pharma Introduces Generic Sugammadex Injection In $1.6 Billion USA Market - Sahi
Sahi
Beyond generics: Glenmark resets agenda with a bold 10-year pivot to global drug innovation, says chairman Saldanha - livemint.com
livemint.com
Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial - Business Standard
Business Standard
Recent context
- ·Q1 FY27 net profit rose to Rs 483 crore, reported as more than a 10-fold YoY increase, with revenue up 23%, per July 31 headlines from CNBC TV18 and NDTV Profit.
- ·New product launches were reported in late July: a generic Sugammadex injection in the US market and an Olanzapine single-dose vial, the latter accompanied by a reported single-day price move.
- ·Chairman Saldanha outlined a stated 10-year pivot toward global drug innovation beyond generics, per a July 7 livemint.com report.
Strengths
- +Debt-to-equity of approximately 0.06x is low in absolute terms and following a falling trend per the persistence data.
- +Quality score of 48 ranks 2nd of 6 tracked pharma peers, ahead of Apollo Hospitals, Cipla, Dr. Reddy's and Max Healthcare.
- +News sentiment skews positive across the last 8 tracked articles (6 positive, 2 neutral, 0 negative), with headlines citing Q1 net profit of Rs 483 crore, 23% revenue growth, and new product launches (generic Sugammadex injection, Olanzapine single-dose vial).
- +Mean analyst rating of 1.67 across 11 analysts (1-5 scale, lower = more constructive).
Weaknesses
- −Free cash flow was positive in only 2 of the years in the tracked persistence window despite 5-year revenue growth of 14.3%, meaning cash generation has lagged reported profitability in most periods.
- −ROE has not exceeded 15% in any tracked year (current ROE 14.07%), with a persistence consistency score of 54/100.
- −5-year earnings growth of 6,575% appears to reflect a low prior-year profit base rather than a sustained compounding rate -- more informative when read alongside the much lower forward PE of 22.73 and the Q1 profit jump to Rs 483 crore.
- −Down 9.41% over the last 3 months and trading below the 50-DMA (Rs 2,220.65), though still above the 200-DMA (Rs 2,098.86); 52-week drawdown stands at 11.47%.
Open questions
- ?Does the 6,575% five-year earnings growth figure reflect a genuinely re-based earnings trajectory, or mostly a low prior-year comparison base?
- ?What is driving free cash flow being positive in only a minority of the tracked years despite double-digit revenue growth -- working capital, capex, or one-off items?
- ?How would the 10-year innovation pivot described by the chairman translate into near-term capital allocation and R&D spend relative to the current 8.02% profit margin?
- ?Why has ROE stayed below the 15% threshold in every tracked year even as the forward PE of 22.73 implies the market is pricing in meaningfully higher near-term earnings?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| GLENMARK | Glenmark Pharmaceuticals Ltd.You're viewing | 46.4 | +14.1% | 48 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹2,190.30
SMA 50
₹2,220.65
SMA 200
₹2,098.86
RSI (14)
45.0 (neutral)
From 52w high
-11.5%
1Y return
+2.4%
3M return
-9.4%
50-DMA
Below
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highFree cash flow was positive in only 2 of the years in the tracked persistence window, despite 5-year revenue growth of 14.3% -- cash generation has lagged reported profitability in most periods.
- mediumROE has not exceeded 15% in any year of the tracked window (roeYearsAbove15 = 0), even with a current ROE of 14.07%; the persistence consistency score sits at 54 out of 100.
- medium5-year earnings growth of 6,575% is an extreme outlier that is consistent with a low prior-year profit base rather than a steady compounding rate -- Q1 net profit rose to Rs 483 crore, reported as a more than 10-fold YoY jump on July 31; this figure is best read alongside the forward PE of 22.73 (vs trailing PE of 46.36) rather than at face value.
- lowPrice is down 9.41% over the last 3 months and trades below the 50-DMA (Rs 2,220.65), though it remains above the 200-DMA (Rs 2,098.86) with RSI at 44.99 (neutral); the stock sits 11.47% below its 52-week high.
Cross-section contradictions
- News sentiment over the last 8 tracked articles is uniformly positive/neutral (6 positive, 2 neutral, 0 negative), driven by a reported >10x YoY Q1 profit jump and 23% revenue growth, yet the stock is up just 2.39% over 1 year and down 9.41% over 3 months, trading below its 50-DMA.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days